1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: During the fiscal quarter ended March 31, 2026, none of our directors or executive officers adopted , modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “ non-Rule 10b5-1 trading arrangement ” as defined in Item 408(c) of Regulation S-K .
+Added: During the fiscal quarter ended June 30, 2026, none of our directors or executive officers adopted , modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “ non-Rule 10b5-1 trading arrangement ” as defined in Item 408(c) of Regulation S-K .
Description of Exhibit
3 unchanged sentences
001-41929) filed with the SEC on January 30, 2024).
−Removed: Amendment No.
−Removed: 1 to Loan and Security Agreement, dated March 5, 2026, by and between Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company, and the Registrant .
Certification of Chief Executive Officer Pursuant to Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
16 unchanged sentences
ARRIVENT BIOPHARMA, INC.
+Added: August 12, 2026
/s/ Zhengbin (Bing) Yao, Ph.D.
2 unchanged sentences
(principal executive officer)
+Added: August 12, 2026
/s/ Winston Kung
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.